Exponent Extends the Runway: EPS Gains, Dividends Up, and a Quiet Path Toward 2023 for EXPO

Overview: a steady 2022 with a shareholder-friendly tilt

Exponent, Inc. (Nasdaq: EXPO) wrapped 2022 with a solid revenue cadence and a disciplined approach to capital allocation. In the fourth quarter, revenues before reimbursements rose 7.9% year over year to $112.6 million, while total revenues climbed 12.2% to $127.4 million. Net income hit $22.5 million for the quarter, or $0.44 per diluted share, up from $20.4 million and $0.38 per diluted share a year earlier. EBITDA came in at $31.1 million (27.6% of revenues before reimbursements), vs. $30.2 million (28.9%) in Q4 2021.

For the full year 2022, the company reported total revenues of $513.3 million and revenues before reimbursements of $463.8 million, up 10.1% and 6.7%, respectively, with foreign exchange effects lifting the growth rate to 8% on the top-line before reimbursements. Net income reached $102.3 million, or $1.96 per diluted share. A tax benefit related to share-based awards of $5.8 million added about $0.11 per diluted share, and the reported consolidated tax rate was 22.6% for 2022 (vs. 19.6% in 2021). EBITDA for the year stood at $137.2 million, or 29.6% of revenues before reimbursements (vs. 30.4% in 2021).

Segment and mix: engineering at the heart of growth

Exponent’s engineering and other scientific segment represented 83% of revenues before reimbursements in both Q4 2022 and the full year. This segment grew 10% in Q4 and 8% for the full year 2022, underscoring broad demand across consumer products, electronics, life sciences, and automotive sectors. The environmental and health segment accounted for the remaining 17% of revenues before reimbursements, with a 2% decline in Q4 and flat performance for the full year; excluding FX, this segment posted a 2% increase in Q4 and a 4% rise for the full year.

Capital allocation: dividends, buybacks, and cash generation

Balance sheet discipline is evident. Exponent paid $49.2 million in dividends during 2022 and repurchased $155.9 million of common stock. The company ended the year with $161.5 million in cash and cash equivalents. In a separate press release, Exponent announced an increase in its quarterly cash dividend from $0.24 to $0.26, with the next distribution slated for March 24, 2023, signaling ongoing confidence in free cash flow generation and capital return to shareholders.

Outlook: where the 2023 revenue forecast meets margin discipline

For the first quarter of 2023, Exponent expects revenues before reimbursements to grow in the high-single to low-double digits, with EBITDA expected to be in the range of 27.5% to 28.2% of revenues before reimbursements. For the full year 2023, managementGuidance calls for revenues before reimbursements to grow in the high-single to low-double digits and EBITDA to come in at 28.0% to 28.5% of revenues before reimbursements.

The tone is practical rather than aspirational: the company frames its strength as a durable, diversified portfolio with a heavy tilt toward the engineering and scientific verticals that have historically benefited from complexity-driven demand. Dr. Catherine Corrigan, President and CEO, and CFO Richard Schlenker emphasize talent recruitment and client relationships as levers for maintaining momentum into 2023.

What this means for investors and sector peers

The Exponent story is less about a single quarter’ s surprise and more about a consistent ability to translate headcount and capability into measurable top- and bottom-line growth. The absence of a published EPS consensus or explicit earnings surprise in the release means there isn’t a formal earnings surprise narrative to compare against the street, but the beat on Q4 2022 revenue before reimbursements versus last year is a clean signal of operating leverage, aided by a favorable mix shift toward higher-margin engineering services.

Shareholders got a double dose of reassurance: a higher dividend and sizable buybacks, financed by continuing cash generation. For peers in the sector, Exponent’s 2023 guidance—particularly the margin band around EBITDA as a share of revenues before reimbursements—offers a template for how to sustain growth while returning capital. As markets weigh demand for specialized engineering and compliance insights against wage pressures and talent scarcity, Exponent’s framework—broad diversification, steady cash returns, and disciplined guidance—looks increasingly replicable, not just aspirational.

Operational and regulatory notes

The company reiterates that EBITDA and EBITDAS are non-GAAP measures defined to provide additional context; management views these metrics as useful for comparing operating performance and cash flow with GAAP figures. The 2022 tax benefit related to share-based awards, the effective tax rate, and the discussion of foreign exchange impacts are all relevant for modeling 2023 results. A conference call to unpack the results is scheduled for February 2, 2023, with details on dialing and a live webcast via the company’s investor relations site.

Bottom line

Exponent’s 2022 results reinforce a narrative of disciplined execution and capital return. With EPS in the low-to-mid single digits for the year and a robust growth trajectory in the core engineering and scientific services, EXPO signals that, even in a period of macro uncertainty, specialized problem-solving remains a defensible and value-creating business. For investors tracking earnings trajectories, the key metrics to watch ahead of 2023 earnings are the revenue before reimbursements growth rate, the EBITDA margin trajectory, and the pace of buybacks and dividends that sustain the company’s cash generation and balance sheet strength.

Notes and disclosures

Exhibits and footnotes in the press release provide definitions of EBITDA and EBITDAS and describe the use of these non-GAAP measures. The filing also covers the conference call details, the impact of foreign exchange on reported results, and the tax treatment of share-based compensation. Investors should consider these elements when modeling EPS and evaluating the revenue forecast for 2023.